Partial replicate design & ABE for the FDA [Design Issues]

posted by nobody – 2017-03-06 14:47 (2933 d 00:18 ago) – Posting: # 17139
Views: 12,084

❝ I asked numerous times here and in Certara’s Extranet why one wants to use a partial replicate design – and never received an answer. :confused:


One guy told me: I'm not going to determine any parameter that is

a - not asked for by authorities
b - might put my product (now or in the furture...) in a bad light compared to reference

In the very beginning of this scaling discussion someone stated (regarding replicate for Reference): "Why should I characterize the REFERENCE product? This should f**ing do the originator!" No joke...

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,666 registered users;
34 visitors (0 registered, 34 guests [including 14 identified bots]).
Forum time: 15:06 CET (Europe/Vienna)

There are only two kinds of scholars;
those who love ideas and those who hate them.    Emile Chartier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5